Vismodegib

{
  "id": "MLC-T-ONC-009271",
  "term": "Vismodegib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat basal cell carcinoma that has spread to other parts of the body, has come back after surgery, or that cannot be treated with surgery or radiation. It is also being studied in the treatment of other types of cancer. Vismodegib blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. It is a type of Hedgehog signaling pathway antagonist. Also called Erivedge and GDC-0449.",
    "An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations."
  ],
  "synonyms": [
    "Erivedge",
    "GDC-0449",
    "Hedgehog antagonist GDC-0449"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vismodegib/"
}